Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KVA12123 Alone and With Pembrolizumab in Advanced Solid Tumors
NCT05708950Phase 2Completed
- Sponsor
- Kineta Inc.
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KVA12123 in solid tumor, sponsored by Kineta Inc.. Started Mar 2023; status: completed.
02
Drugs
KVA12123
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05708950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05708950.